The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 Billion in 2024 ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

The European Commission has granted marketing authorisation for Novo Nordisk’s adult diabetes ... company’s latest prefilled insulin pen, FlexTouch, which has an easy auto-injector mechanism.

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

Novo Nordisk employs around 30,000 people in Denmark ... and type-2 diabetes patients that it had scaled back making insulin pens in South Africa. Without those pens, type 1 diabetics had to ...

For five years, insulin manufacturer Novo Nordisk agrees to cap out-of-pocket cost of its insulin treatments at $35 per month, and provide free insulin to the neediest Minnesotans.

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Ellison says the settlement requires Novo Nordisk to provide insulin products—including ... per monthly prescription (3 vials or 2 packs of pens) for customers paying with cash.